Crinetics Pharmaceuticals (CRNX) Scheduled to Post Earnings on Thursday

Crinetics Pharmaceuticals (NASDAQ:CRNX) will be releasing its earnings data after the market closes on Thursday, May 9th. Analysts expect Crinetics Pharmaceuticals to post earnings of ($0.84) per share for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link.

Crinetics Pharmaceuticals (NASDAQ:CRNX) last announced its quarterly earnings data on Wednesday, February 28th. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.01). Crinetics Pharmaceuticals had a negative return on equity of 52.93% and a negative net margin of 4,223.27%. During the same period last year, the business earned ($0.84) EPS. The company’s revenue for the quarter was down 100.0% on a year-over-year basis. On average, analysts expect Crinetics Pharmaceuticals to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Crinetics Pharmaceuticals Trading Up 2.0 %

NASDAQ CRNX traded up $0.94 on Tuesday, reaching $47.44. The stock had a trading volume of 171,707 shares, compared to its average volume of 755,228. The company has a market capitalization of $3.74 billion, a price-to-earnings ratio of -12.57 and a beta of 0.63. Crinetics Pharmaceuticals has a 1 year low of $15.76 and a 1 year high of $49.58. The business has a 50 day moving average price of $43.99 and a 200 day moving average price of $37.54.

Insider Transactions at Crinetics Pharmaceuticals

In other Crinetics Pharmaceuticals news, CEO Richard Scott Struthers sold 40,951 shares of the business’s stock in a transaction dated Thursday, April 4th. The stock was sold at an average price of $49.17, for a total transaction of $2,013,560.67. Following the sale, the chief executive officer now owns 237,835 shares in the company, valued at approximately $11,694,346.95. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Crinetics Pharmaceuticals news, Director Stephanie Okey sold 17,500 shares of the firm’s stock in a transaction on Thursday, March 28th. The stock was sold at an average price of $46.38, for a total value of $811,650.00. Following the completion of the sale, the director now directly owns 6,000 shares of the company’s stock, valued at approximately $278,280. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Richard Scott Struthers sold 40,951 shares of the company’s stock in a transaction on Thursday, April 4th. The shares were sold at an average price of $49.17, for a total value of $2,013,560.67. Following the completion of the transaction, the chief executive officer now directly owns 237,835 shares in the company, valued at approximately $11,694,346.95. The disclosure for this sale can be found here. Insiders have sold a total of 187,216 shares of company stock valued at $8,509,397 in the last 90 days. Insiders own 7.00% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have commented on CRNX. Citigroup began coverage on Crinetics Pharmaceuticals in a report on Wednesday, March 6th. They issued a “buy” rating and a $68.00 price target for the company. Robert W. Baird raised their price target on shares of Crinetics Pharmaceuticals from $45.00 to $52.00 and gave the stock an “outperform” rating in a research note on Thursday, February 29th. Jonestrading raised their price objective on Crinetics Pharmaceuticals from $52.00 to $56.00 and gave the company a “buy” rating in a research report on Wednesday, March 20th. JMP Securities reaffirmed a “market outperform” rating and issued a $80.00 price objective on shares of Crinetics Pharmaceuticals in a report on Thursday, March 28th. Finally, Morgan Stanley started coverage on Crinetics Pharmaceuticals in a research note on Tuesday, January 16th. They issued an “overweight” rating and a $50.00 price target on the stock. One analyst has rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $57.58.

Crinetics Pharmaceuticals Company Profile

Crinetics Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors.